Ranbaxy facilities searched by FDA

Share this article:
Federal officials Wednesday conducted a search of the New Jersey offices and manufacturing facilities of Indian generic drugmaker Ranbaxy Laboratories. A company spokesman said in published reports that the action came as a surprise. “We’re not aware of any wrongdoing,” Ranbaxy spokesman Charles Caprariello said in a published report. “We’re cooperating and providing them with (material) even today.” Caprariello said officials from the FDA searched two Ranbaxy sites in New Jersey – a manufacturing plant in New Brunswick and administrative offices in Princeton. He declined to comment on whether the officials removed anything from the sites. “We’re working with the authorities to address the issues and hopefully resolve everything so we can get back to business as normal,” he said. Caprariello told The Wall Street Journal that the management team remains intact and employees are being informed about what has happened. Inquires to the FDA from news agencies about the searches were referred to the Justice Department. A Justice Department spokeswoman told the Associated Press, “We don’t comment on ongoing investigations.” Ranbaxy is based in Gurgaon, India and is that nation’s largest drug company. Last month, the company received approval to make a generic version of Pfizer’s blockbuster antidepressant Zoloft. Other generic drugmakers already had approval for generic versions.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...